ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is December 30, 2020. The rights plan expires, without any further action being required to be taken by ADMA’s Board of Directors, on December 15, 2021.

Here is the original post:
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Excerpt from:
SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $42.00 per share. All of the shares to be sold in the offering are being sold by Phathom. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $94.5 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 21, 2020.

Read the original post:
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is the first product approved from MacroGenics’ promising pipeline. The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

See original here:
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

Advance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate Advance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

Original post:
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

Meticore Reviews – Is this best Fatburner Supplement – Product Review by Mike Vaughn

Read the original:
Meticore Reviews - Is this best Fatburner Supplement - Product Review by Mike Vaughn

Drone X Pro Reviews – Evergreen Drone worth it? – Product Review by Mike Vaughn

The Drone X Pro is an interesting drone that can help you with your shots and bring you photos which you can't imagine. With its long battery life and flight time it's a great beginner drone. The Drone X Pro is an interesting drone that can help you with your shots and bring you photos which you can't imagine. With its long battery life and flight time it's a great beginner drone.

Here is the original post:
Drone X Pro Reviews - Evergreen Drone worth it? - Product Review by Mike Vaughn

Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Continue reading here:
Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Sequana Medical Announces January 2021 Investor Conference Schedule

GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference.

See original here:
Sequana Medical Announces January 2021 Investor Conference Schedule

Evaxion Biotech Appoints Marianne Søgaard as Chairwoman

COPENHAGEN, Denmark, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S, a clinical-stage biotechnology company developing AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the appointment of previously practicing commercial, technology and corporate lawyer Marianne Søgaard as Chairwoman of the Board of Directors.

Read the original here:
Evaxion Biotech Appoints Marianne Søgaard as Chairwoman